# US 2026/0092926 A1 · Biological status classification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092926 A1
- Document ID: US20260092926A1
- Status: Published application
- Kind: A1
- Application number: 19/410,807
- Filed: 2025-12-05
- Published: 2026-04-02
- Earliest claimed: 2019-08-02
- Assignees: Randox Laboratories Limited
- Applicants: Randox Laboratories Ltd
- Inventors: Paul John Innocenzi; Stephen Peter Fitzgerald; Ivan Robert Mcconnell
- Web page: https://patentgrep.com/patent/US20260092926A1

## CPC

- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G16H 10/20: for electronic clinical trials or questionnaires
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/60: relating to nutrition control, e.g. diets
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H 70/60: relating to pathologies
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

There is provided a method of classifying a biological status of an individual. The method comprising: obtaining a biological sample from a patient; obtaining health-related information from the patient, said information including patient gender; analysing the sample to identify a quantity of each of 2 or more endogenous analytes in the sample; comparing the analyte quantities to reference data from healthy individuals to classify the patient as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition. The reference data includes data derived from a group of biological samples of individuals having the same gender as the patient and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process as used to analyse the patient sample, the process being monitored to maintain a predetermined level of consistency.

## Claims

### Claim 1

In a method of treating an individual in which a biological sample of the individual is analysed, using a diagnostic unit, to identify a quantity of each of 2 or more endogenous analytes in the sample and the analyte quantities are compared to reference data to classify the individual as healthy, pre-diseased, at risk of disease or diseased for at least one health-related condition, and upon finding the individual is prediseased, at risk of disease, or diseased, applying an appropriate medical treatment to the individual, the improvement comprising:
performing the analysis using reference data derived from a group of biological samples of individuals having the same gender as the individual and not having a need for medical treatment for a disease or illness, each biological sample of the group of biological samples having been analysed by the same process and using the same diagnostic unit as used to analyse the individual sample;
wherein the analysis of the sample further includes measuring for one or more exogenous analytes and classifying, based upon the presence, absence or a concentration of biochemicals in the sample, the individual as disease free without exogenous contaminant, disease free with exogenous toxic biochemical, pre-disease without exogenous toxic biochemical, pre-disease with exogenous toxic biochemical, disease present without exogenous toxic biochemical or disease present with exogenous toxic biochemical, and
wherein applying the appropriate medical treatment to an individual who is classified as disease free with exogenous toxic biochemical or pre-disease with exogenous toxic biochemical comprises referring the individual to a nutritional and personal care specialist.

### Claim 2 (depends on 1)

The method according to claim 1, wherein each biological sample of the group of biological samples is a biological sample obtained from individuals at a single site, and wherein:
the single site is the same site as the site at which the individual sample is obtained; or
the single site is in a home region of the individual.

### Claim 3 (depends on 1)

The method according to claim 1, wherein health-related information includes age, and the individual is in the same age cohort of the individuals of the group of biological samples.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the endogenous analytes measured are selected from: Glucose, Albumin, HbA1c, HDL, Sodium, Cholesterol, WBC, Calcium, Creatinine, ALT, Urea, Cystatin C, CRP, AAT, GGT, Total bilirubin, Lipase, TAS, H. pylori, Ferritin, CK Nac, Insulin, FT4, IgG, Magnesium, TSH, Vitamin D, IgE, Myoglobin, Uric acid, ASO, Vitamin B12, Rheumatoid factor, Iron, Transferrin, AST, Folic acid, FT3, Pancreatic amylase, and ALP;
and wherein for endogenous analytes glucose, sodium, cholesterol, WBC, calcium, ALT, cystatin C, CRP, AAT, total bilirubin, lipase, TAS, albumin, HbA1c, HDL, urea, insulin, and magnesium the reference range values assigned to each analyte corresponds to upper and lower values of the 95% percentile calculated from biological samples of the group of biological samples.

### Claim 5 (depends on 1)

The method according to claim 1, further comprising: when the comparison indicates the individual is pre-diseased, at risk of disease or diseased, analysing a further biological sample obtained from the individual after a predetermined time interval.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the one or more exogenous analytes are selected from: Bisphenol A, Phthalates (Me, Et, diethyl, tBu), Parabens (Me, Et), Bisphenol A bis(2,3-dihydroxypropyl) ether, 2,4-dihydroxybenzophenone (BP-1), 2-hydroxy-4-methoxybenzophenone (BP-3), Benzophenone-4, Octyl methoxycinnamate (OMC or octinoxate), Triclosan, Triclocarban, BP-A, BP-F, BP-B, BP-E, BP-S, HPP, 4,4-dihydroxybenzophenone, Metaldehyde, Carbendazim, MCPA, Dimethyl tetrachloroterephthalate, Oxadixyl, Pendimethalin, Carbetamide, Mecoprop, Propyzamide, Triclopyr, Quinmerac, Chlorpyrifos, Fluoxpyr, Chlortoluron, Metoxuron, 2,4-D, Endrin, Heptachlor, Toxaphene, Aldrin, Chlordane, Dieldrin, Mirex, Chlordecone, PCBs, Polychlorinated DBFs, PBDEs, PBBs, Hexachlorobutadiene, Lindane, DDT, Pentachlorobenzene, Hexachlorobenzene, Pentachlorophenol, PFOSA, Endosulfan, Hexabromocyclodecane, PCN, and PCDBs.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the individual sample is obtained in a diagnostic unit co-located with a fitness unit and/or a nutritional unit; and
wherein if the individual is classified as pre-diseased, at risk of disease or diseased based on the analysis, the individual is put on a healthcare regime provided by a medical professional based on the identified quantity of one or more of the analytes.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the analysis is conducted using one or more analysers, each analyser used for a specific analyte in each respective sample being of the same model analyser, and:
(a) each analyser used for the specific analyte is the same analyser as used for a previous analysis of the specific analyte in a sample from the same individual;
(b) each analyser used for the specific analyte is derived from a single manufacturer; or
(c) the reagents used during sample analysis are derived from a single manufacturer.

### Claim 9 (depends on 1)

The method according to claim 1, wherein when sample analysis comprises:
transitioning from a first analyser to a further analyser, wherein the same model analyser or a newer model of the analyser is used as the further analyser; and analysing one or more samples from one or more individuals that have been analysed on the first analyser using the further analyser.

### Claim 10 (depends on 1)

The method according to claim 1, wherein for each biological sample obtained from an individual, the analysis of the respective sample is carried out on the same day or the analysis of the respective sample is carried out in the same location.
